Debiopharm Signs Canadian Partner for Sanvar®
Complete the form below to unlock access to ALL audio articles.
Debiopharm Group announces the signature of a License and Supply Agreement with Medical Futures Inc., a Canadian based Gastroenterology focused speciality pharmaceutical company, for the Canadian distribution rights to SANVAR® IR (SANVAR®), an immediate release formulation.
The product, developed by Debiopharm for the treatment of acute esophageal variceal bleeding (EVB), is currently under review for approval by the Canadian Health Authorities.
In addition to purchasing the product directly from Debiopharm, Medical Futures Inc. is responsible for upfront and milestone payments.
“Medical Futures Inc. is excited about partnering with Debiopharm for SANVAR®,” says Dr. Par Nijhawan, Chief Medical Officer of Medical Futures Inc., who believes that SANVAR® will help improve the options available for life threatening variceal bleeds.
“Medical Futures has created a therapeutic focus and a strong product offering for the gastroenterology market in Canada,” says Dr. Loïc Maurel, President and Chief Executive Officer of Debiovision Inc., the Debiopharm Affiliate in Canada. “With SANVAR® in their capable hands, we are confident of its success in an important market for us.”
